FS008

FS008 is a preclinical-stage oncology asset developed by Foreseen Biotechnology for the treatment of solid tumors. The drug was discovered using the company's proprietary AI-powered translational proteomics platform, which identifies novel tumor-associated antigens by analyzing high-resolution mass spectrometry data from primary patient tissues. While Foreseen Biotechnology focuses on the development of high-affinity antibodies and antibody-drug conjugates (ADCs), the specific molecular target and modality of FS008 have not yet been publicly disclosed. The program is part of a broader pipeline of first-in-class therapeutics aimed at addressing previously unreachable or uncharacterized oncology targets.